These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 14614663

  • 1. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
    Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C, Infectious Diseases Society of America.
    Clin Infect Dis; 2003 Dec 01; 37(11):1405-33. PubMed ID: 14614663
    [No Abstract] [Full Text] [Related]

  • 2. [Atypical pathogens of pneumonia acquired in ambulant persons].
    Tuschy P, Lorenz J.
    Dtsch Med Wochenschr; 2004 Mar 05; 129(10):503-8. PubMed ID: 14986239
    [No Abstract] [Full Text] [Related]

  • 3. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM.
    J Manag Care Pharm; 2009 Mar 05; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [Abstract] [Full Text] [Related]

  • 4. Prescription of macrolides in community-acquired pneumonia: science or art?
    Rello J.
    Chest; 1998 May 05; 113(5):1155-8. PubMed ID: 9596285
    [No Abstract] [Full Text] [Related]

  • 5. [Therapy of non-nosocomial pneumonia].
    Drömann D, Schaaf B.
    MMW Fortschr Med; 2008 Jan 24; 150(3-4):31-4; quiz 35. PubMed ID: 18326476
    [No Abstract] [Full Text] [Related]

  • 6. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM, Risso K, Hyvernat H, Landraud L, Vassallo M, Dellamonica J, de Salvador F, Cua E, Bernardin G.
    Med Mal Infect; 2010 Jun 24; 40(6):347-51. PubMed ID: 20172672
    [Abstract] [Full Text] [Related]

  • 7. Community-acquired pneumonia and positive urinary antigen tests: Factors associated with targeted antibiotic therapy.
    Mothes A, Léotard S, Nicolle I, Smets A, Chirio D, Rotomondo C, Tiger F, Del Giudice P, Perrin C, Néri D, Foucault C, Della Guardia M, Hyvernat H, Roger PM, Réseau Infectio-PACA-Est.
    Med Mal Infect; 2016 Oct 24; 46(7):365-371. PubMed ID: 27377444
    [Abstract] [Full Text] [Related]

  • 8. C-reactive protein for discriminating treatment failure from slow responding pneumonia.
    Ruiz-González A, Falguera M, Porcel JM, Martínez-Alonso M, Cabezas P, Geijo P, Boixeda R, Dueñas C, Armengou A, Capdevila JA, Serrano R.
    Eur J Intern Med; 2010 Dec 24; 21(6):548-52. PubMed ID: 21111942
    [Abstract] [Full Text] [Related]

  • 9. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
    Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG.
    Arch Intern Med; 2000 May 22; 160(10):1399-408. PubMed ID: 10826451
    [Abstract] [Full Text] [Related]

  • 10. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S.
    J Infect; 2009 Sep 22; 59(3):222-4. PubMed ID: 19592113
    [No Abstract] [Full Text] [Related]

  • 11. [Comparative analysis of guidelines for the treatment of community-acquired pneumonias].
    Rodríguez de Castro F.
    Arch Bronconeumol; 1999 Jun 22; 35(6):253-6. PubMed ID: 10410203
    [No Abstract] [Full Text] [Related]

  • 12. Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy.
    Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H, Watanabe A.
    J Infect Chemother; 2017 Nov 22; 23(11):727-732. PubMed ID: 28951197
    [Abstract] [Full Text] [Related]

  • 13. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR.
    Clin Infect Dis; 2002 Sep 01; 35(5):565-9. PubMed ID: 12173130
    [No Abstract] [Full Text] [Related]

  • 14. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ, Arnold C, Bassetti S.
    Swiss Med Wkly; 2013 Sep 01; 143():w13870. PubMed ID: 24089030
    [Abstract] [Full Text] [Related]

  • 15. [Therapy of pneumonia].
    Stille W.
    ZFA (Stuttgart); 1980 Apr 10; 56(10):677-80. PubMed ID: 6998163
    [No Abstract] [Full Text] [Related]

  • 16. [Antibiotic treatment for legionellosis].
    Calbo E, Garau J.
    Enferm Infecc Microbiol Clin; 2006 Apr 10; 24(6):357-9. PubMed ID: 16792935
    [No Abstract] [Full Text] [Related]

  • 17. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
    Falguera M, Ruiz-González A, Schoenenberger JA, Touzón C, Gázquez I, Galindo C, Porcel JM.
    Thorax; 2010 Feb 10; 65(2):101-6. PubMed ID: 19703825
    [Abstract] [Full Text] [Related]

  • 18. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
    Bartlett JG.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S232-6. PubMed ID: 18986295
    [Abstract] [Full Text] [Related]

  • 19. Legionella species community-acquired pneumonia.
    Kane GC.
    Chest; 1997 Jan 01; 111(1):254. PubMed ID: 8996030
    [No Abstract] [Full Text] [Related]

  • 20. Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents.
    Marrie TJ.
    Infect Dis Clin North Am; 2004 Dec 01; 18(4):829-41. PubMed ID: 15555827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.